Alterity Therapeutics (ASX:ATH) has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as the company prepares to advance its lead therapy into a pivotal late-stage clinical trial. …
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech